Exits

EpiTherapeutics

Discovery of new pharmaceuticals for the treatment of cancer within the field of epigenetics.

Invested in 2010

Acquired by Gilead in 2015

Based in Foster City, California, USA 

Lundbeckfonden Emerge

Nyheder

Lundbeckfonden bag største serie A-investering i dansk biotek nogensinde
11. marts 2019
Andreas Jurgeit
Ny Partner til Lundbeckfonden Emerge
17. december 2018
IO Biotech announces first patient dosed in global phase I/II clinical trial for the first-line treatment of patients with metastatic non-small cell lung cancer
2. oktober 2018